Anticipatory prescribing in community end-of-life care: systematic review and narrative synthesis of the evidence since 2017

Ben Bowers 1,2, Bárbara Costa Pereira Antunes 1, Simon Etkind 1, Sarah A Hopkins 1, Isaac Winterburn 3, Isla Kuhn 4, Kristian Pollock 5, Stephen Barclay 1

ABSTRACT

Background The anticipatory prescribing of injectable medications is recommended practice in controlling distressing symptoms in the last days of life. A 2017 systematic review found practice and guidance was based on inadequate evidence. Since then, there has been considerable additional research, warranting a new review.

Aim To review the evidence published since 2017 concerning anticipatory prescribing of injectable medications for adults at the end-of-life in the community, to inform practice and guidance.

Design Systematic review and narrative synthesis.

Methods Nine literature databases were searched from May 2017 to March 2022, alongside reference, citation and journal hand-searches. Gough’s Weight of Evidence framework was used to appraise included studies.

Results Twenty-eight papers were included in the synthesis. Evidence published since 2017 shows that standardised prescribing of four medications for anticipated symptoms is commonplace in the UK; evidence of practices in other countries is limited. There is limited data on how often medications are administered in the community. Prescriptions are ‘accepted’ by family caregivers despite inadequate explanations and they generally appreciate having access to medications. Robust evidence of the clinical and cost-effectiveness of anticipatory prescribing remains absent.

Conclusion The evidence underpinning anticipatory prescribing practice and policy remains based primarily on healthcare professionals’ perceptions that the intervention is reassuring, provides effective, timely symptom relief in the community and prevents crisis hospital admissions. There is still inadequate evidence regarding optimal medications and dose ranges, and the effectiveness of these prescriptions. Patient and family caregiver experiences of anticipatory prescriptions warrant urgent investigation.

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC

⇒ Anticipatory prescribing has become established good practice in controlling distressing symptoms for patients dying in the community.
⇒ Current anticipatory prescribing guidance and practice is based on an inadequate evidence base.

WHAT THIS STUDY ADDS

⇒ The prescribing of anticipatory medications is a significant event for patients and families and signifies the imminence of death.
⇒ There remains inadequate evidence to draw conclusions about the impact of anticipatory prescriptions on symptom control or crisis hospital admissions.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND POLICY

⇒ Robust research is needed to investigate the clinical effectiveness, cost-effectiveness, safety and acceptability of anticipatory prescribing.
⇒ Patient and family caregiver experiences of anticipatory prescriptions and their involvement in decisions to administer medication require urgent investigation.

INTRODUCTION

Anticipatory prescribing of injectable medication is considered essential for timely management of distressing last-days-of-life symptoms in the community.1–3 A key feature of anticipatory prescribing is that the medications are
prescribed ahead of possible need: ‘just in case’. Medications are typically prescribed for symptoms of pain, shortness of breath, agitation, nausea and vomiting and noisy respiratory tract secretions. Anticipatory prescriptions include controlled drugs and those with the potential for misuse including opioids and benzodiazepines. These are dispensed and an accompanying prescription and administration authorisation chart is completed. Once this is done, permission has been granted for nurses, paramedics and general practitioners (GPs) to use (administer) the medications subcutaneously based on their clinical assessment that the person is dying and needs them for symptom management. The chart details the medications, indications and dose, typically with dose ranges that enable some discretion when using the drugs. In some countries, including Australia and parts of the UK, appropriately trained family caregivers (family and friends) can administer these injectable medications with support. Administration may be with a needle and syringe or needle-free technique, where the syringe is connected to a pre-existing subcutaneous catheter.

Anticipatory prescribing is actively promoted in end-of-life care guidance documents internationally, in part recently due to the rapid increase in the numbers of terminally ill patients dying at home and in care homes during the COVID-19 pandemic. The intervention has become an embedded part of symptom control care and is widely perceived by clinicians and policymakers to be a key end-of-life clinical intervention. However, two UK independent reviews into the mismanagement of injectable medications have raised serious concerns about inappropriate practices in prescribing and using anticipatory medications.

Four years ago, we systematically reviewed and synthesised evidence supporting the practice of anticipatory prescribing for dying adults in the community, and found that it has been founded on an inadequate evidence base. Care was based primarily on the belief of doctors and nurses that access to these medications reassures patients and their families, effectively controls symptoms and prevents crisis hospital admissions. There was no reliable data on how often medications are prescribed or subsequently used in the community. There was inadequate evidence to allow conclusions to be drawn about anticipatory prescribing in terms of its cost-effectiveness, safety, impact on patient-reported symptoms or prevention of crisis hospital admissions. No studies had examined patient views and experiences of anticipatory prescribing. Studies of family caregiver opinions were limited to evaluations of family carer administration of injectable medications. In summary, there was paucity of high-quality research to inform care.

Since our original review (search undertaken in 2017), a considerable amount of new research has been conducted to develop the anticipatory prescribing evidence base, not least due to the challenges of the COVID-19 pandemic. A synthesis of this new body of research is warranted to determine how knowledge has advanced.

AIM

We aimed to synthesise the evidence published concerning anticipatory prescribing of injectable medications for adults at the end-of-life in the community, to inform practice and guidance. We included papers published from May 2017 onwards, building on our original systematic review. The focus of our review is exclusively on injectable medications, as this is the most widespread form of anticipatory prescribing, requires specific training and has been highlighted to have potential for misuse.

REVIEW QUESTIONS

Regarding the anticipatory prescribing of injectable medications for adults in the community approaching the end of their lives:
1. What is current practice?
2. What are the attitudes of patients?
3. What are the attitudes of family caregivers?
4. What are the attitudes of community healthcare professionals?
5. What is its impact on patient comfort and symptom control?
6. Is it cost-effective?

METHODS

We conducted a systematic review and narrative synthesis of empirical evidence published since May 2017. The review protocol was registered with PROSPERO (reg. no. CRD42016052108). We use the same research questions and methods (including search strategy, eligibility and data synthesis approaches) as our original review to allow ease of comparison for clinicians, researchers and policymakers. We report the new evidence published since May 2017 in the results and narrative synthesis. In the discussion section, we draw comparisons to what our original review found to highlight how the evidence base has evolved, and to identify what the new empirical evidence adds to the existing knowledge base.

The search strategy was developed and refined with the review team’s Information Scientist (IK). The search was conducted using nine databases: Medline, CINAHL, Embase, Web of Science, PsycINFO, Cochrane Library, Social Care Online, HMIC and King’s Fund. Box 1 details the Boolean search strategy used in Medline; searches in the other databases were adapted from this strategy (online supplemental material 1).

All databases were searched from 1 May 2017 to 1 March 2022. The digital archives for BMJ Supportive & Palliative Care and Palliative Medicine were also hand-searched for published papers from May 2017 to March 2022. These two journals were chosen as they...
contained for the largest number of eligible studies from the initial search strategy and from our original review. Reference and citation searches of all included papers were undertaken.

Papers were included if they presented new empirical data on the anticipatory prescribing of injectable medications for end-of-life symptom control in the community, published in English. The review was limited to papers where patient participants were aged 18 years and over. Published case studies, audits and conference abstracts were included, mirroring the inclusion criteria for our original systematic review.23 Studies were excluded if they reported on the reactive prescribing of injectable medication after symptoms occurred. Box 2 details the review inclusion and exclusion criteria.

Search results were uploaded into Endnote X9 and duplicates removed. BB screened titles for eligibility using the inclusion/exclusion criteria. After exclusion of irrelevant and duplicate titles, abstracts were independently screened for eligibility by three reviewers (BB, BCPA, SAH), with disagreements resolved by consensus. Full-text papers were assessed for eligibility by BB, with a second review by BCPA or SAH, where eligibility was uncertain. From the 2379 records identified, 10 papers met the inclusion criteria. Reference, citation and hand searches identified a further 18 papers; of which, 13 were published conference abstracts not registered in databases.

A review-specific data extraction form was used to record participant characteristics and methods from each included paper, and the results relevant to each of the six review questions (online supplemental material 2). In tandem to the data extraction process, two members of the review team (BB, BCPA, SAH, SE and IW) independently assessed each paper in terms of its internal validity, appropriateness and contribution in answering the review questions, using a review-specific version of Gough’s Weight of Evidence (WoE) criteria (box 3).33 This modified version had been successfully used in our original systematic review. Where one or more of the reviewers were an author of an included study, two non-authors conducted the WoE assessment. Discrepancies in assessment decisions were discussed between reviewers and final scores were agreed through consensus.

Extracted data were entered into Excel to aid the narrative synthesis of the included papers.31 32 An
inductive narrative synthesis approach was chosen for its applicability in interpreting and integrating heterogeneous study methods and qualitative and quantitative evidence. The following three iterative stages were involved, replicating the approach adopted in our original review:

1. Study descriptions and results were tabulated based on the sample population, methods and the research questions the results answered.

2. BB, a clinical academic palliative care nurse with experience in conducting narrative synthesises, completed an inductive narrative analysis to identify the main, recurrent and divergent evidence across the studies in answering each research question. The similarities and differences between the studies, including methodological approaches and research methods, context, characteristics of participants and findings were considered throughout the iterative inductive synthesis. The significance and applicability of findings from studies conducted by researchers from different disciplinary and epistemological positions were debated with BCPA, KP and SB; consensus in the synthesis was reached. The synthesis was further refined through discussion of the review results and their implications with the Cambridge Positive Ageing and Cambridge Palliative and End-of-Life Care Patient and Public Involvement Groups, the review team, clinicians and interested members of the public (including people with experience of being family caregivers) through a series of presentations.

3. The WoE score of papers informed the synthesis. Papers judged as having an overall high WoE (D) score were considered more robust and appropriate in answering the review questions than papers with a medium score in the synthesis. Results from papers with an overall low WoE score were regarded as inadequate to draw conclusions from unless they supported the findings of papers rated as WoE medium or high. We included papers with an overall low WoE score in the synthesis to demonstrate the overall evidence base, highlighting the gaps in knowledge and the need for future research.

RESULTS

Figure 1 details the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of the review and the number of papers that met the criteria for inclusion.

A total of 28 papers, reporting on 27 studies, were included in the synthesis: 14 research papers and 14 conference abstracts. Different elements of one study were reported in two papers: both papers were treated as individual study units in the analysis as they presented different findings. Papers reported on practice in the UK (n=19), Australia (n=5), Australia and New Zealand (n=1), Canada (n=1), British Isles (n=1) and Norway (n=1). Published papers’ methods included qualitative interviews with healthcare professionals (n=9), qualitative interviews with family caregivers (n=5), retrospective patient notes reviews (n=10), staff or family questionnaires (n=5), clinical audits (n=2), guidance document analysis (n=2), qualitative interviews with patients (n=1), a randomised pilot trial (n=1) and quasirandomised control trial (n=1); eight papers reported on multiple-methods, including those mentioned above. Online supplemental material 3 summarises the included papers and their overall WoE: 6 were rated as high, 17 medium and 5 low.

What is current practice?

Twenty-one studies have reported on anticipatory prescribing practice in the community: these were rated as WoE low to high and conducted primarily in the UK and Australia. Surveys of healthcare professionals and analysis of governance documents, predominately rated as WoE low and medium, suggest that anticipatory prescribing is widespread established end-of-life practice in the UK, with some services also permitting the prescribing of anticipatory...
prescribed via syringe pumps/drivers (continuous subcutaneous infusions).5 19 37 38 Anticipatory prescriptions appear to be less commonplace in Australia, Canada and Norway, with the intervention focused primarily on supporting populations with a terminal cancer diagnosis.17 17 39–41

Prescribing practices

The frequency of anticipatory prescribing in the community has been investigated by five studies6 17 42–44 rated as WoE low to high. Prescribing rates vary from 14% to 96% of deaths in the community (home or care home), dependant on underlying terminal conditions, geographical location and community healthcare services involved.6 17 42–44 However, data are often limited by focusing on populations receiving specialist palliative care or inadequate definitions of anticipatory prescribing.17 42 44 Two studies, assessed as WoE medium and high, utilised deceased patient records in general practice populations and identified a prescribing rate of 44%43 and 51%.6 The likelihood of being issued an anticipatory prescription is significantly higher for patients with a recorded preferred place of death (OR: 34; 95% CI: 15 to 77; p<0.001) and for patients receiving specialist palliative care involvement (OR 7; 95% CI: 3 to 19; p<0.001).6

Anticipatory prescriptions are initiated independently by GPs or at the request of community nurses and specialist palliative care teams in the UK and Norway.6 39 45 In parts of Australia, prescriptions are reliant on nurses prompting GPs to consider doing so17 40 46; two Australian studies, both rated as WoE low, identified that a referral to specialist palliative care services triggered a standard request for GPs to initiate prescribing.17 46

There is considerable variation in the timing of anticipatory prescribing prior to death.6 41 Prescriptions range from 0 to 1212 days before death,6 with a median timing of 14 to 22 days before death for patients with terminal cancer conditions and 6–12 days for those with non-cancer conditions.6 43 Three UK studies, rated as WoE high, found prescribing clinicians issued prescriptions well in advance of anticipated need, even if they were unlikely to be used6 45 47; the presence of prescriptions in the home are used as a sign to alert other visiting clinicians to the terminal nature of the patient’s condition.45

The standardised prescribing of four injectable medications for symptoms of pain, nausea and vomiting, agitation and noisy respiratory tract secretions is commonplace in the UK and prompted by local and national guidance.5 6 42–44 45 48 Two UK studies, rated as WoE medium and high, found anticipatory medications to start via syringe pumps/drivers were prescribed for between 29% and 33% of patients along side individual ‘as required’ injections in the community.6 57 This practice is dependent on clinician preferences and local healthcare cultures,6 38 45 and
has not been reported on in other countries. Opioids are commonly prescribed for pain control in the UK and Australia, the sedative midazolam is frequently prescribed for agitation. Specialist palliative care clinicians report prescribing midazolam and opioids in higher doses when anticipating a possible catastrophic terminal event, such as bleeding or airway obstruction.

Administration practices
The literature concerning the use of prescribed anticipatory medications remains limited. GPs typically rely on visiting nurses and paramedics to assess when to start medications and update them about their use. Four studies, rated as WoE medium to high, reported that between 37% and 64% of anticipatory prescriptions were used; these studies refer to small numbers of patients, often receiving specialist palliative care. Six studies identified that medications are most frequently used for symptoms of pain, agitation and nausea and vomiting. These studies relied on recollections of medications used or incomplete records, limiting the reliability of data.

There is insufficient published research regarding the timing of first medication use prior to death. One small-scale study, rated as WoE medium, found patients with a diagnosis of cancer, frailty or dementia first received medications a median of 4 days before death. A service evaluation, rated as WoE medium, reported the median timing between prescription and first drug administration was 9 days for patients with cancer (range 0–368 days), and 61 days for those with non-cancer conditions (range 3–298 days). Both studies were limited by having partial access to patient records.

The time from nurses receiving a family request to administer medication to giving the dose can vary greatly, with a median time of 105 min reported in one UK multisite study rated as WoE high. Two Australian and one UK paper have reported on initiatives to train family caregivers to assess symptoms and give injectable medication, with or without direct clinical guidance. A survey of healthcare professionals working in the UK and Ireland, undertaken at the start of the COVID-19 pandemic and rated as WoE high, reported that numerous community healthcare services were considering this option, in anticipation of end-of-life care needs overwhelming community healthcare resources. The extent to which these policy changes have been put in place in practice, or will persist after the pandemic, remains unclear.

What are the attitudes of patients?
Only one published study has directly investigated patients’ attitudes regarding anticipatory prescribing. The interview study, rated as WoE high, reported the views of six case study participants where anticipatory medications had been prescribed but not yet used: it was unclear how many of these participants were patients or family members. The prescribing of anticipatory medications was a significant event for patients and clearly signified the imminence of death. No published studies have investigated patients’ views and experiences of the administration of prescribed anticipatory medications.

What are the attitudes of family caregivers?
Five studies have investigated family caregiver perspectives regarding nurses overseeing and administering prescribed medications: this is standard practice in the UK and several other countries. Two qualitative interview studies, rated WoE medium to high, identified anticipatory prescriptions were ‘accepted’ into the home by family caregivers despite receiving inadequate explanations about medications, often because symptoms of suffering were expected at the end-of-life. A survey of bereaved family caregivers (n=38) and two interview studies (n=18 and n=2), rated as WoE medium, found that anticipatory prescriptions were generally viewed as being helpful. However, an unknown number of family caregivers reported feeling distressed when they realised that the prescription indicated that death was imminent. Family caregivers expressed concerns about storing controlled drugs in the house, experienced difficulties in getting nurses to visit to administer the medications in a timely manner or expressed ambivalence regarding the helpfulness of medication.

Four of the five studies were only reported briefly in conference abstracts. Overall, it is not clear from the available studies if anticipatory prescribing was reassuring, a cause for concern or both.

Family caregiver attitudes are clearer regarding initiatives where they administer (give) the injections. Four UK and Australian studies, rated as WoE low to high, found that family caregivers reported the training and experience of administering anticipatory medications to be acceptable. Self-reported confidence in administering injections increased with practice. However, a service improvement initiative, rated as WoE low, specified that relatively few family caregivers were willing or able to take on the role. A UK multicentre randomised pilot trial, rated as WoE high, found that family caregivers selected by patients to give their injectable medications tended to have a healthcare background; most family caregivers struggled to recognise the difference between symptoms and worried about accidentally hastening death by giving injections. Despite these concerns, family caregivers reported that being able to administer injections increased feelings of empowerment and control; the median time taken for family caregivers to administer injections was 5 min.

What are the attitudes of community healthcare professionals?
The range of views of healthcare professionals towards anticipatory prescribing are reported in
15 studies of community nurses, palliative care nurses, care home staff, pharmacists, GPs and palliative doctors in the UK, Australia, New Zealand and Norway (five rated as WoE high, eight medium and two low). The majority of the studies focused on the perceptions of GPs and nurses.9 17 19 39 40 42 43–45 49 53 55 56 No published studies have investigated emergency ambulance paramedics’ views and experiences.

Healthcare professionals’ views are largely positive towards anticipatory prescribing. GPs and nurses perceive the intervention provides proactive and effective symptom control, helps prevent crisis hospital admissions and reassures patients, families and clinical teams.9 17 37 39 40 45 46 49 55 56 One survey study, rated as WoE medium, found palliative care doctors are uncertain whether anticipatory prescriptions for catastrophic terminal events are beneficial, as patients often die before medication can be given or take effect and conversations about unlikely events may cause disproportionate and unnecessary anxiety.49 However, doctors prescribe medications out of concern that patients may experience considerable distress if they are not available.49 The lack of robust evidence and guidance to inform this practice is a concern for palliative care doctors.

Key components of successful anticipatory prescribing are identified in 11 studies with healthcare professionals, rated as WoE low to high. Effective communication and close partnership working between GPs and community nurses are perceived to be vital in effective prescribing and timely medication administration; mutual respect for each other’s skills, expertise and ease of access to each other are considered essential.39 40 45 46 56 Healthcare professionals appreciate standardised systems and local policies that prompt timely prescribing and recommend safe starting doses.42 45 53 55 Two studies, both rated WoE high, identified that GP and nurse-led anticipatory prescribing conversations with patient and families are initiated in a way intended to lessen worries about the medication and their potential symbolic significance, while ensuring prescriptions are accepted.45 47 The ready availability of stock in community pharmacies is considered vital in ensuring prescriptions are dispensed in a timely way.19 40

Some prescribers are wary about the safety of anticipatory prescribing, especially prescribing strong opioids ahead of need since they remain accountable for drug errors or misuse.17 40 45 GPs were reluctant to leave controlled drugs in the home if there was a history of drug misuse in the family.40 45 and rely on visiting nurses to monitor potential risks.19 45 Concerns about medication wastage can also be a barrier to prescribing.19

The administration of anticipatory medications raises safety concerns for healthcare professionals. For example, deciding when to administer medication causes less experienced nurses considerable unease, and some nurses report that they lack the confidence to initiate injections or adjust doses.39 40 One interview study, rated as WoE high, identified that nurses value clear instructions on when to administer the medication and what doses to give.39 Doctors and nurses report adverse patient events have occurred when medications were administered without an adequate clinical assessment of need or the wrong medication was given.37 40 49 Views on the safety of prescribing anticipatory syringe pumps/drivers are divided: some consider them vital in ensuring timely symptom control,37 while others view it as unsafe practice that can lead to inappropriate medications and dosing being initiated.37 Some nurses and GPs think it too burdensome on family caregivers to train them to administer injectable medication, especially if families express concerns about accelerating death by giving medication.9 Nurses are cautious and selective about who they approach to take on this role.9 46

What is its impact on patient comfort and symptom control?
The impact of anticipatory prescribing on patient comfort and symptoms has been reported in two studies.9 50 A survey of bereaved family caregivers,50 rated as WoE medium, found that just over half of the respondents reported that the medication was used, usually for pain or agitation, with good effect. Among the patients who required medications, problems family caregivers reported included deciding when to call for help and delays in clinicians attending to administer medication. A randomised pilot trial,9 rated as WoE high, found family carer and health-care professional-reported patient symptom scores improved after the administration of injectable medications; however, there was considerable missing data on reported comfort before and after injections when family caregivers administered these. No published studies have reported on patient perceived comfort and symptom control.

Is it cost-effective?
Anticipatory prescribing is a relatively low-cost intervention. Two UK records review studies, both rated as WoE medium, have calculated the costs of prescriptions. The first study identified the median cost of prescriptions as £43.17 per patient; the second study calculated a prescription cost of £50 per patient.48 Both studies identified that haloperidol, frequently prescribed for possible symptoms of nausea and vomiting, accounted for much of these costs. The median cost of administered medications was £2.16 per patient, resulting in substantial drug wastage costs.35

The relationship between anticipatory prescribing and subsequent service use remains unclear.41 One
population-level and retrospective cohort study, rated as WoE medium, has measured the impact of anticipatory prescribing on service use. The study identified that anticipatory prescribing alongside putting in place a home death care plan was associated with reductions in hospitalisation or emergency department visits in the last 6 months of life; both interventions increased the likelihood of patients dying in the community. However, this study did not account for confounding variables, such as family support and preferences regarding hospital admissions. It is possible that anticipatory prescribing serves as a proxy indicator of the healthcare team’s awareness of the imminence of death and their planning for community-based care.

**DISCUSSION**

**Summary of findings**

This systematic literature review identified the following key findings about anticipatory prescribing in the community:

1. Prescribing practices vary in relation to community setting, proximity of prescriptions to death and patient populations. The standardised prescribing of four medications for anticipated symptoms is commonplace in the UK; evidence of practices in other countries remains limited. There is limited reliable data on how often medications are administered in the community.

2. Only one small study has directly investigated the experiences or views of patients. The prescribing of anticipatory medications appears to be a significant event for patients and signifies the imminence of death. Further research is urgently needed.

3. Anticipatory prescriptions are accepted by family caregivers despite inadequate explanations and they generally appreciate having access to medications; family caregivers also express ambivalence regarding the helpfulness of medication and have safety concerns. Family caregivers who take on the role of administering anticipatory medications appreciate being able to provide symptom relief, although some struggle with assessing symptoms and worry injections may hasten death.

4. Healthcare professionals perceive that anticipatory prescriptions enable effective symptom control, help prevent crisis hospital admissions and provide reassurance for everyone involved. Effective teamwork plays a central role in the prescription and use of anticipatory medication. GPs and nurses also express safety concerns and nurses struggle with decisions to start injections and when adjusting doses.

5. Robust evidence of clinical effectiveness remains absent. Two studies suggest the intervention may contribute to symptom relief.

6. Anticipatory prescribing is a relatively low-cost intervention, although most medications appear to go unused. Robust evidence of cost-effectiveness remains absent.

This review identifies the increase in high-quality studies concerning anticipatory prescribing since our original review in 2017 (table 1). However, most studies in both reviews reported on single sites or sampled from populations receiving specialist palliative care input, limiting the generalisability/transferability of findings. In this synthesis, we found similar numbers of papers to the original review, although over a much shorter publication period. This indicates there has recently been increased research interest in anticipatory prescribing. Evidence was limited to the UK, Norway, Australia, New Zealand and Canada. Although anticipatory prescribing is considered best practice internationally, published empirical research from other countries remains rare.

Grey literature was not included in this review. Consequently, our methods did not capture non-peer-reviewed evidence; a methodological decision was made to include only peer-reviewed publications, replicating the original review inclusion and exclusion criteria. Conference abstracts were included and offer useful insights into care, although all scored WoE low to medium due to limited information on their methods. Conference abstracts accounted for the majority of studies found through journal hand searches: these were not recorded in the nine databases.

**Table 1** Number of papers included in the current synthesis and original review

<table>
<thead>
<tr>
<th>Review question</th>
<th>Number of papers in the current review answering each research question and overall WoE (D) scores</th>
<th>Number of papers in original review answering each research question and overall WoE (D) scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is current practice?</td>
<td>21 papers: 6 high, 11 medium and 4 low WoE (D) scores</td>
<td>26 papers: 3 high, 16 medium and 7 low WoE (D) scores</td>
</tr>
<tr>
<td>What are the attitudes of patients?</td>
<td>1 paper: high WoE (D) score</td>
<td>No papers on patient views or experiences. 2 papers refer to practitioner interpretations of patient views: 1 medium and 1 low overall WoE (D) scores</td>
</tr>
<tr>
<td>What are the attitudes of family caregivers?</td>
<td>9 papers: 2 high, 5 medium and 2 low WoE (D) scores</td>
<td>5 papers: 2 medium and 3 low overall WoE (D) scores</td>
</tr>
<tr>
<td>What are the attitudes of community healthcare professionals?</td>
<td>15 papers: 5 high, 8 medium and 2 low WoE (D) scores</td>
<td>21 papers: 3 high, 13 medium and 5 low overall WoE (D) scores</td>
</tr>
<tr>
<td>What is its impact on patient comfort and symptom control?</td>
<td>2 papers: 1 high and 1 medium WoE (D) scores</td>
<td>3 papers: 2 medium and 1 low overall WoE (D) scores</td>
</tr>
<tr>
<td>Is it cost-effective?</td>
<td>3 papers: 3 medium WoE (D) scores</td>
<td>9 papers: 6 medium and 3 low overall WoE (D) scores</td>
</tr>
</tbody>
</table>

*Studies from the original review were not included in the results and narrative synthesis: they are detailed in the table to give an overview of the overall evidence base.

WoE, Weight of Evidence.
This highlights the value of the complementary search strategies.

It was difficult to separate anticipatory prescribing before symptoms arise from reactive prescribing after symptoms occur in several studies. Two reviewers independently applied the definition of ‘the prescribing of injectable medications ahead of need to control terminal symptoms’ and reached consensus by discussion when eligibility was unclear. Studies were excluded when their methods reported on the prescribing and use of injectable end-of-life medications generally. The evidence underpinning anticipatory prescribing practice and policy remains based primarily on healthcare professionals’ perceptions and experiences that the intervention is reassuring and provides effective, timely symptom relief. However, healthcare professionals also introduce the subject of anticipatory prescribing in a way that plays down the purpose and significance of prescriptions, expecting patients and families to be cautious about having injectable medications, including strong opioids, in the home.

The limited research to date exploring the views and experiences of patients and family caregivers suggest that the intervention is both reassuring and a source of concern. Only one published study to date, identified in this review, has explored patients’ views regarding anticipatory prescriptions. Practice and policy based primarily on healthcare professionals’ perceptions risks misunderstanding how anticipatory prescriptions are viewed by other key stakeholders.

Patient and family caregiver experiences of anticipatory prescriptions and their involvement in decisions to administer medication with nurses require urgent investigation. This was also a key recommendation from the original systematic review findings; this priority area has still received inadequate research attention, possibly due to ethical concerns about interviewing dying patients and their families. Recent published research has focused primarily on the views of bereaved family caregivers of patients who received specialist palliative care; many patients and families do not receive this level of specialist input and care, and may have diverse experiences. We have recently completed in-depth longitudinal interviews exploring patients’, family caregivers’ and their healthcare professionals’ views and experiences of decisions to prescribe and use of anticipatory medications.

Having access to anticipatory medications may not, by itself, adequately resolve the issues the intervention sets out to address: ensuring timely, effective symptom control in the community. Building on the knowledge from our earlier review, it is now clear anticipatory prescribing is a complex intervention involving multiple steps, several layers of teamwork and nuanced, skilled judgements about both when to prescribe and use medication. These processes are prone to miscon- 

When multiple healthcare professionals and services are involved.

Studies have repeatedly identified that families are unsure when to access professional help with symptom control; when they do, they report experiencing difficulties in getting nurses to visit to administer injectable medications in a timely way. Community nurses also struggle with decisions to administer anticipatory medications and less experienced nurses’ report being over-cautious when giving injections, fearing causing over-sedation or hastening death. Paramedic experiences of using anticipatory medications remain unknown and require exploration as the workforce is involved in crisis end-of-life symptom management at home. How lone-working nurses and paramedics can be best supported in assessing risk and making skilled, nuanced decisions to use anticipatory medications warrant careful consideration in practice and policy.

Prior to the start of the COVID-19 pandemic, it was very unusual for family caregivers in the UK to give injectable anticipatory medications, whereas it is routine practice in parts of Australia and New Zealand. Different approaches reflect accepted healthcare norms and practices rather than being attributable to the rurality and remoteness of settings. Healthcare responses to the pandemic have accelerated the possibility that family caregivers might take on the role of giving anticipatory medications with suitable training and clinical support. Findings from the current review highlight this must be considered carefully in practice on a case-by-case basis rather than being used to manage deficits in over-stretched community healthcare services.

Family and friends should not perceive that they are obligated or under any pressure to take on this additional responsibility at a particularly stressful time. The alternative of nurse administered injectable medications should be discussed alongside this possibility. Families are vulnerable to the pressure of professional persuasion to take on additional responsibilities in managing symptoms, even if inadvertent. The potential benefits and emotional burdens for family caregivers taking on the role of administering anticipatory medications also needs further investigation and detailed evaluations or what works, when and why before it becomes widespread international practice and policy.

Our current review findings emphasise the need for prospective clinical trials that investigate the impact of anticipatory prescribing on patient symptom control and rates of crisis hospital admissions. Despite consensus guidance promoting individualised prescribing based on likely needs and patient preferences, our current review found evidence that standardised prescriptions of four medications and set dose ranges are now more commonplace and actively promoted by local healthcare systems, at least in some parts of the UK. Standardised prescribing recommendations have been shaped by experiences of symptom profiles of patients dying with terminal
cancer and may not apply to other health conditions such as dementia. However, standardised prescriptions may have their place. Prescribing medication for future unknowns, often weeks in advance, is an inherently uncertain process, especially if patients have not previously experienced symptoms that have required strong opioids or sedatives.\(^{15} 24\) Prescribing standardised, small starting doses and ranges enables the trialling of anticipatory medications, with subsequent prescriptions adjusted to individual need; whether standardised prescriptions of four medications and set doses are appropriate, regularly reviewed and tailored to individual need once medications are commenced remains unknown. Research and nuanced clinical guidance to improve tailored anticipatory prescribing clinical decision-making is warranted.

Current anticipatory prescribing recommendations are based on inadequate knowledge of the diversity of dying symptom profiles, the clinical effectiveness of prescriptions and their potential adverse effects.\(^{15} 74\) There is a call in English end-of-life care guidance for a cluster-randomised control trial that compares the clinical effectiveness of anticipatory prescriptions against prescription in response to symptoms. This may pose a challenge, as anticipatory prescribing is widespread established practice in several countries. However, different types of anticipatory prescribing practices could be compared, including standardised prescribing versus individualised prescribing.

**CONCLUSION**

This systematic review highlights that anticipatory prescribing remains recommended and widespread community practice in the UK, and several other countries, despite a limited evidence base. The evidence underpinning anticipatory prescribing practice and policy remains based primarily on healthcare professionals’ perceptions and experiences that the intervention offers reassurance and provides effective, timely symptom relief in the community. There is still limited evidence concerning likely symptom profiles and which medications and dose ranges are needed. The views and experiences of patients and their family caregivers towards anticipatory prescribing need further investigation. Urgent research is necessary to investigate the clinical effectiveness, cost-effectiveness, safety and acceptability of different anticipatory prescribing practices.

**Twitter** Ben Bowers @Ben_Bowers_, Bárbara Costa Pereira Antunes @B_CP_Antunes, Sarah A Hopkins @saahopkins and Isla Kuhn @ilik21

**Contributors** BB, SB, IK and KP designed the study. IK and BB carried out the searches. BB led on the screening and analysis with input from BCPA, SE, SAH, JW, SB and KP. All authors contributed to the interpretation of the results and the writing of the manuscript. BB is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The lead author (BB) affirms that the manuscript is an honest, accurate, and transparent account of the review being reported.

**Funding** This work was supported by the Wellcome Trust [225577/Z/22/Z]. BB received funding by the National Institute for Health Research (NIHR) School for Primary Care Research [SPCR-146]. SI is funded as a Health Education England Clinical Lecturer. SAH is jointly funded by The Dunhill Medical Trust and British Geriatrics Society [JBG205]. SB is supported by the NIHR Applied Research Collaboration East of England (NIHR ARC EoE) at Cambridgeshire and Peterborough NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information. No previously unpublished primary data are included in the paper. All data relevant to the systematic review are included in the paper or uploaded as supplementary information.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iDs**

Ben Bowers http://orcid.org/0000-0001-6772-2620

Bárbara Costa Pereira Antunes http://orcid.org/0000-0003-1655-7391

Sarah A Hopkins http://orcid.org/0000-0002-5089-6496

Isaac Winterburn http://orcid.org/0000-0003-4844-7496

Stephen Barclay http://orcid.org/0000-0002-4505-7743

**REFERENCES**


5. Coyle S, Sinden R, Wignall-Coyle J, et al. Continuous subcutaneous infusion: is community anticipatory prescribing...
and administration safe? BMJ Support Palliat Care 2021;bmjspcare-2021-003259.
42 Cornish C, French S. 73 Introduction of a community palliative care drug chart to facilitate Individualised and
appropriate anticipatory prescribing. BMJ Support & Palliative Care; March 2018

43 Rainbow E, Faull C. P-120 Describing anticipatory medicine use in the community at the end of life. BMJ Support Palliat Care; November 2017


48 Tran T, Lee C, Ross J. P-141 Anticipatory Prescribing at end-of-life: Do we need to change practice? BMJ Supportive & Palliative Care; November 2021


51 Hedges V, Wee B, Bond C. 81 A qualitative study of family carer experience of anticipatory prescribing of injectable medications for end of life care at home. BMJ Support Palliat Care; March 2021


53 Rainbow E. P-121 a thematic analysis of anticipatory medicine use in the community at end of life. BMJ Support Palliative Care; November 2017

54 Lewis M, Heneghan J, Burdon J. 107 A service evaluation of a new policy to support Carers giving subcutaneous anticipatory medications at home at end of life within Southern Derbyshire, population of 607,000. BMJ Supportive & Palliative Care; 2021


Supplemental Material 1

Boolean search strategy for the nine databases

All searches were run 1st March 2022

Medline via Ovid

Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) May 2017 to March 2022

((palliative adj medicine adj kit*) or (liverpool adj care adj pathway*) or ((end adj2 life) adj2 ((care adj plan*) or (care adj pathway*))) or (gold adj standard* adj framework*) or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or (care adj plan*) or (core adj "4") or (core adj four)) adj3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or (just adj in adj case) or PRN or (pro adj re adj nata) or (as adj required))) ti, ab. and (exp Terminal Care/ or exp Palliative Care/ or exp "Hospice and Palliative Care Nursing"/ or exp death/ or exp Palliative Medicine/ or exp Terminally ill/ or ((end adj2 life) or ((final* or last*) adj1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or (end adj stage) or dying or (body adj2 (shutdown or shut* down or deteriorat*)) or deathbed).ti,ab.

Embase via Ovid

May 2017 to March 2022

((palliative adj medicine adj kit*) or (liverpool adj care adj pathway*) or ((end adj2 life) adj2 ((care adj plan*) or (care adj pathway*))) or (gold adj standard* adj framework*) or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or (care adj plan*) or (core adj "4") or (core adj four)) adj3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or (just adj in adj case) or PRN or (pro adj re adj nata) or (as adj required))) ti, ab. and (exp *Terminal Care/ or exp *Palliative therapy/ or exp *palliative nursing/ or exp *palliative treatment/ or exp *hospice care/ or exp
Supplemental Material 1

Boolean search strategy for the nine databases

*hospice/ or exp *Terminally Ill Patient/ or exp *dying/ or ((end adj2 life) or ((final* or last*) adj1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or (end adj stage) or dying or (body adj2 (shutdown or shut* down or deteriorat*)) or deathbed).ti,ab.)

CINAHL via Ebsco

TI (("palliative medicine kit"") or ("liverpool care pathway"") or (end N2 life) N2 (("care plan"") or ("care pathway"))) or ("gold standard framework") or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or ("care plan") or ("core 4") or ("core four")).ti,ab.)

And

TI ((end N2 life) or ((final* or last*) N1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or ("end stage") or dying or (body N2 (shutdown or shut* down or deteriorat*)) or deathbed) or AB ((end N2 life) or ((final* or last*) N1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or ("end stage") or dying or (body N2 (shutdown or shut* down or deteriorat*)) or deathbed) or (MH "Terminal Care") OR (MH "Palliative Care") OR (MH "Hospice and Palliative Nursing") OR (MH "Hospice Patients") OR (MH "Hospices") OR (MH "Hospice Care") OR (MH "Terminally Ill Patients") OR (MH "Death")

PsycINFO via Ebsco

TI (("palliative medicine kit") or ("liverpool care pathway") or (end N2 life) N2 (("care plan") or ("care pathway"))) or ("gold standard framework") or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or ("care plan") or ("core 4") or ("core four")).ti,ab.)
Supplemental Material 1

Boolean search strategy for the nine databases

- medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or ("care plan*") or ("core 4") or ("core four") N3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or ("just in case") or PRN or ("pro re nata") or ("as required"))) or AB ("palliative medicine kit*") or ("liverpool care pathway*") or (end N2 life) N2 ("care plan*") or ("care pathway*")) or ("gold standard* framework*") or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or ("care plan*") or ("core 4") or ("core four")). N3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or ("just in case") or PRN or ("pro re nata") or ("as required")))

And

TI (end N2 life) or ((final* or last*) N1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or ("end stage") or dying or (body N2 (shutdown or shut* down or deteriorat*)) or deathbed or AB (end N2 life) or ((final* or last*) N1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or ("end stage") or dying or (body N2 (shutdown or shut* down or deteriorat*)) or deathbed or (DE "Terminally Ill Patients") OR (DE "Palliative Care") OR (DE "Death and Dying" OR DE "Euthanasia" OR DE "Parental Death") OR (DE "Hospice")

Web of Science Core Collection

(("palliative medicine kit*") or ("liverpool care pathway*") or (end near/2 life) near/2 ("care plan*") or ("care pathway*"))) or ("gold standard* framework*")) or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or ("care plan*") or ("core 4") or ("core four"). near/3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or ("just in case") or PRN or ("pro re nata") or ("as required"))) and (end near/2 life) or (final* or last*) near/1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or ("end stage") or dying or deathbed or (body near/2 deteriorat*) or (body near/2 "shut* down") or (body near/2 shutdown))
Supplemental Material 1

Boolean search strategy for the nine databases

Cochrane Library

All Results (52)
- Cochrane Reviews (57)
- All
- Review
- Protocol
- Other Reviews (5)
- Trials (27)
- Methods Studies (0)
- Technology Assessments (1)
- Economic Evaluations (1)
- Cochrane Groups (0)

#1 ("palliative medicine kit*") or ("liverpool care pathway*") or ((end near/2 life) near/2 ("care plan*") or ("care pathway*")) or ("gold standard* framework*") or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or ("care plan*") or ("core 4") or ("core four")) near/3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or ("just in case") or PRN or ("pro re nata") or ("as required")))

#2 (end near/2 life) or ((final* or last*) near/1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or ("end stage") or dying or deathbed or (body near/2 deteriorat*) or (body near/2 "shut* down") or (body near/2 shutdown))

#3 MeSH descriptor: [Terminal Care] explode all trees

#4 MeSH descriptor: [Palliative Care] explode all trees

#5 MeSH descriptor: [Hospice and Palliative Care Nursing] explode all trees

#6 MeSH descriptor: [Palliative Medicine] explode all trees

#7 MeSH descriptor: [Death] explode all trees

#8 #2 or #3 or #4 or #5 or #6 or #7

#9 #1 and #8
Supplemental Material 1

Boolean search strategy for the nine databases

Social Care Online

May 2017 to March 2022

"palliative medicine kit" or "liverpool care pathway" or "end of life" and care plan or care pathway or "gold standard framework"

And

"palliative medicine kit" or "liverpool care pathway" or "end of life" and care plan or care pathway or "gold standard framework"

"palliative medicine kit" or "liverpool care pathway" or "end of life" and care plan or care pathway or "gold standard framework"

And

palliative or terminal or death or dying or last or final or "end stage" or “body shutdown” or “body shut down”

title

medicine or drug or prescription or prescribing or medication or “core 4” or "core four" or packet or pack or box or kit or "care plan"

and

palliative or terminal or death or dying or last or final or "end stage" or body shutdown or body shut down

and

crisis or comfort or comfortable or anticipate or anticipatory or anticiaption or preemptive or pre-emptive or “just in case” or PRN or "pro re nata" or "as required"
Supplemental Material 1

Boolean search strategy for the nine databases

HMIC via Ovid

((palliative adj medicine adj kit*) or (liverpool adj care adj pathway*) or ((end adj2 life)_adj2 ((care adj plan*) or (care adj pathway*))) or (gold adj standard* adj framework*) or ((prescrib* or prescription* or medicat* or medicine* or drug* or pharma or pharmaceutical* or packet* or pack* or pak* or box* or kit* or (care adj plan*) or (core adj "4") or (core adj four))) adj3 (crisis* or comfort* or anticipate* or anticipatory or anticipation or preemptive or pre-emptive or (just adj in adj case) or PRN or (pro adj re adj nata) or (as adj required))).ti,ab. and (exp terminal care/ or exp Terminal nursing/ or exp Terminal illness/ or exp Hospices/ or exp "End of life care"/ or exp Palliative care/ or exp Death/ or ((end adj2 life) or ((final* or last*) adj1 (hour* or day* or minute* or week* or month* or moment*)) or palliat* or terminal* or (end adj stage) or dying or (body adj2 (shutdown or shut* down or deteriorat*)) or deathbed).ti,ab.)

Kings Fund

Results from May 2017 to March 2022:

The rising cost of medicines to the NHS What's the story?

Innovative approaches to end of life care
https://www.kingsfund.org.uk/events/innovative-approaches-end-life-care
## Supplemental Material 2

### Data Extraction Tool

<table>
<thead>
<tr>
<th>Details of publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>First author</td>
</tr>
<tr>
<td>Reference</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aims</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country of study</td>
</tr>
<tr>
<td>Recruitment</td>
</tr>
</tbody>
</table>

- Characteristics of participants:
  - Number
  - Setting (home, hospital etc)
  - Age / sex / social class / ethnicity

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of fieldwork</td>
</tr>
<tr>
<td>Research methods</td>
</tr>
<tr>
<td>Analysis</td>
</tr>
</tbody>
</table>

### Key findings relevant to review

1) What is current practice?  
Who prescribes, for whom, proximity to death?  
Who administers?  
Absence of AP?

2) What are the attitudes of patients to AP?  
Patients’ acceptance / views

3) What are the attitudes of family caregivers to AP?  
Carers’ acceptance / views

4) What are the attitudes of community healthcare professionals to AP?  
HCPs’ acceptance of AP, concerns, views re use, barriers, facilitators, etc.
Supplemental Material 2

Data Extraction Tool

5) Evidence for clinical effectiveness?

**Clinical:** comfort / symptom control (who reported)

6) Evidence for cost / cost-effectiveness?

**Service use:** admission avoidance, place of death, healthcare activity, etc.

**Cost:** costs of drugs, admissions, healthcare activity, etc.

Author(s) conclusion(s)

Reviewer assessment of the internal validity, appropriateness and contribution of the study in answering the relevant research questions (Gough’s WoE)

<table>
<thead>
<tr>
<th>Weight of Evidence A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coherence and integrity of the evidence <em>in its own terms</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight of Evidence B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appropriateness of <em>form of evidence</em> for answering review question</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight of Evidence C</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Relevance of the evidence</em> for answering review question</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight of Evidence D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall assessment of study contribution to answering review question</td>
</tr>
</tbody>
</table>
### Supplemental Material 3

#### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Staats et al. (2018) [1] Norway | 18 community and cancer care nurses working in one region | To increase the understanding concerning community nurse experience with anticipatory medication in symptom management for the terminally ill | - The assessment of symptoms and when to administer prescribed drugs is delegated to nurses  
- Good communication and meetings with GPs deemed essential in facilitating the appropriate use of medication  
- Recently qualified nurses did not feel confident in assessing the need for medication  
- Nurses worked alone mainly, this caused great variation in medication kit administration  
- There was vulnerability felt in relation to using medication kits at night  
- Nurses felt more confident continuing a dose that had been started by the day staff than being the one to initiate the medication for the first time | H H H – H |
| Bowers et al. (2022) [2] UK | 329 deceased patients with 12 GP practices in two counties | To investigate the frequency, timing and recorded circumstances of anticipatory medication prescribing for patients living at home and in residential care | - 51% prescribed anticipatory medication, between 0 and 1212 days (median 17 days) before death  
- The likelihood of AMs prescribing was significantly higher for patients with a recorded preferred place of death (OR 34; 95% CI 15–77; p < 0.001) and specialist palliative care involvement (OR 7; 95% CI 3–19; p < 0.001)  
- Most patients (92%) were prescribed anticipatory medications for all five common end-of-life symptoms: pain, breathlessness, nausea and vomiting, agitation and respiratory tract secretions.  
- Standardised prescribing was commonplace and prompted by primary care electronic end-of-life templates (63% of the patients prescribed medications) | H H H – H |
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Bowers et al. (2020) [3] UK | 13 GPs working in two counties | To explore GPs’ decision-making processes in the prescribing and use of anticipatory medications for patients at the end of life. *Methods:* Qualitative interviews. Qualitative analysis. | • GPs generally prescribed drugs while patients were relatively stable, as it helped them manage the uncertainty.  
• The prescribing of anticipatory medications was recognised as a harbinger of death for patients and their families.  
• GPs often presented anticipatory medications as a clinical recommendation to ensure patients and families accept the prescription.  
• In some cases, prescribed drugs remained in the home for months or went unused.  
• GPs relied on nurses to assess when to administer drugs and keep them updated about their use: easy access to one another and good communication was perceived to be crucial. | H, H, H – H |
| Poolman et al. (2020) [4] UK | 40 patient, family caregiver dyads from three regions; 22 completed the follow-up visit.  
*Interviews:* 12 bereaved family caregivers; 20 healthcare professionals: 3 GPs; 14 community nurses; and 3 specialist palliative care nurses. | To assess if family caregiver administration of as-needed injectable medication for common breakthrough symptoms in patients dying at home is feasible and acceptable.  
*Methods:* Multicentre randomised control pilot trial, including qualitative interviews with family caregivers and healthcare professionals. Descriptive statistics and qualitative analysis. | • Family care confidence in administering medication increased over time; family caregivers required different amounts of training to feel confident.  
• The intervention was acceptable to family caregivers, who found it helpful and reassuring.  
• The median time to administer medication in the intervention group was 5 minutes versus 105 minutes for the usual-care group.  
• Many caregivers in the study intervention arm had previous healthcare training.  
• Caregivers worried about accidentally hastening death.  
• Clinicians had a positive view of the intervention in terms of its effects on symptom management and benefits.  
• Clinicians were very careful about who to approach to take part and were concerned about potential family caregiver distress regarding the ‘last injection’ before death. | H, H, M – H |
### Supplemental Material 3

#### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Pollock et al. (2021) [5] UK | Workstream one: 21 bereaved family caregivers (13 had experience of anticipatory medications). 40 healthcare professionals: 16 palliative care nurses; 8 community nurses; 3 specialist nurses; 7 GPs; 4 pharmacists; and 2 consultants. Workstream two: 21 patient cases, each of which included 1-5 participants (6 case study participants had experience of anticipatory medications): 15 patients; 19 family caregivers; 14 healthcare professionals. | To explore how patients, their family caregivers and the healthcare professionals who support them engage in the tasks of managing complex medication regimens and routines of care for patients who are approaching the end of life at home. Methods: Qualitative interviews and focus groups, interviews over time based on patient cases, observations and medical records review (8 cases). Qualitative analysis | • 46% of family caregivers in workstream one reported anticipatory medications were used.  
• Clinicians preferred to prescribe medication well in advance of anticipated need or even when there was not a strong likelihood that they would be needed.  
• Anticipatory prescribing was a significant event for patients and their families, clearly signifying the imminence of death.  
• Family caregivers valued the availability of anticipatory medication when they were needed.  
• Several family caregivers reported medication were prescribed without accompanying explanation or discussion.  
• Some participants stored the drugs out of sight to keep them safe so that they were not reminded of their purpose.  
• Clinicians tended to be vague and avoided opportunities for providing explicit information.  
• Family caregivers worried about the storage of controlled drugs in the house and their role in administering these to patients. | H H M – H |
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Antunes et al. (2020) [6] UK and Ireland | 261 palliative care doctors, GPs, community nurses, clinical nurse specialists, pharmacists and other professional groups | To investigate clinicians’ experiences concerning changes in anticipatory prescribing during the Covid-19 pandemic and their recommendations for change. Methods: Survey with open and closed questions. Descriptive and qualitative analysis. | - Reported changes in practice related to possible administration by family or social caregivers and drug availability.  
- At the same time, clinical contact and patient assessment were changing to telephone or video rather than in person.  
- Fear of waste and cost are factors that limit the amount of anticipatory prescribing in the community.  
- Having access 24 hours for anticipatory medication prescriptions and drugs in key in enabling rapid response and symptom control. | M H H – H |
| Morgan, et al., (2022) [7] UK | 164 deceased patients prescribed anticipatory medications, registered with 12 GP practices in two counties | To identify the prescription, usage and wastage costs of anticipatory medications for patients living at home and in residential care. Methods: Retrospective notes review. Statistical analysis. | - Median anticipatory prescription cost was £43.17 (IQR: £38.98-£60.47, range £8.76 to £229.82)  
- Median administration prescription cost was £2.16 (IQR: £0.00-£12.09, range £0.00 to £83.14)  
- Median wastage was £41.47 (IQR: £29.15-£54.33, range £0.00 to £195.36)  
- Haloperidol and cyclizine, contributed 49% of total wastage costs. | M H M – M |
| Ryan et al. (2020a) [8] UK | 89 healthcare professionals from across the UK: 25 palliative care nurses; 24 palliative consultants; 22 GPs, community nurses and pharmacists | To explore the views of UK healthcare professionals about best practice and areas in need of improvement in anticipatory prescribing. Methods: Focus groups and survey. Descriptive statistics and qualitative analysis. | - 38% were confident that anticipatory prescribing was done well.  
- 20% were concerned about unsafe practice.  
- Top-tips for achieving practice included reducing cross-system complexity by unifying documents and electronic systems. | M H M – M |
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilsworth et al. (2021) [9] UK</td>
<td>18 bereaved family caregivers receiving care from one specialist palliative care team</td>
<td>To explore family caregivers experiences of anticipatory prescribing and identify ways to improve practice Methods: Qualitative interviews. Qualitative analysis</td>
<td>• Some family caregivers reported feeling shocked and distressed when they realised that the medications indicated that their relative was approaching end of life • Concerns associated with obtaining, storing and eventually disposing of medications • Systems barriers, including sourcing the right professional support in a timely manner to administer medication often proved problematic</td>
<td>M H M – M</td>
</tr>
<tr>
<td>Johnston et al. (2019) [10] Australia</td>
<td>40 staff in one area: 20 carers; 13 nurses; 4 team leaders; 2 managers; 1 geriatrician (findings relate to these participants)</td>
<td>To understand the experience and impact of integrating a specialist palliative care model on care homes residents, relatives and staff Methods: Qualitative interviews. Qualitative framework analysis</td>
<td>• Perception of care home staff that anticipatory prescribing done more because of having palliative care nurse practitioner input in identifying and reviewing deteriorating patients • Prescriptions perceived as a useful tool for preventing hospital admissions • GP-nurse trust crucial in prescribing and use: trust between GPs and the registered nurses at the facilities improved with specialist palliative nurse input</td>
<td>M H M – M</td>
</tr>
</tbody>
</table>
## Supplemental Material 3
### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Healy et al. (2018) [11] | Australia 93 Family caregivers, allocated to one of three intervention arms in a large region: group 1: 27; group 2: 30; group 3: 36 | To explore differences in laycarers’ confidence in administering subcutaneous injections depending on whether an family caregiver, nurse or pharmacist prepared injections Methods: Quasi-randomised control trial. Statistical analysis | • Family caregivers self-reported confidence with experience of administering injections went from 5.3 for the first injection to 6.1 for subsequent injections on a 7-point (7 = extremely confident) Likert scale  
• Neither the mean level of confidence nor change in confidence over time differed significantly across groups | M M M – M          |
| Cornish and French (2018) [12] | UK 49 deceased patients on community nursing caseloads in two counties. 20 GPs | To evaluate whether a new community anticipatory medication chart and guidance facilitates safe, appropriate and consistent prescribing Methods: Audit of medical records; survey of GPs. Descriptive statistics | • 47 of the 49 expected deaths had an anticipatory medication chart in place  
• Deceased patients were prescribed: opioid (84%), antiemetic (97%), antisecretory (94%) and anxiolytic (94%)  
• All GPs surveyed agreed that the new chart facilitates safe and appropriate anticipatory prescribing | M M M – M          |
### Supplemental Material 3

#### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tran et al. (2021) [13] UK</td>
<td>76 patients receiving the care of who received care from one specialist palliative care organisation (hospice)</td>
<td>To evaluate anticipatory prescribing practices against current local guidelines &lt;br&gt; Methods: Retrospective records review. Descriptive statistics</td>
<td>• All patients were prescribed and dispensed four medications for: pain, agitation, secretions and nausea/vomiting &lt;br&gt; • There was close adherence to local guidelines (choice of drug, dose) &lt;br&gt; • Most commonly prescribed drugs were: midazolam 99%; glycopyrronium 97%; haloperidol 88%; morphine 61% &lt;br&gt; • 64% had stats given at end-of-life: 53% for pain, 41% for agitation, 24% for secretions; 16% for nausea &lt;br&gt; • Community nurses and paramedics administered the medications &lt;br&gt; • All four medications cost approximately £50 per patient: haloperidol accounted for 60% of costs and was not often used</td>
<td>M H L – M</td>
</tr>
<tr>
<td>Rainbow and Faull (2017) [14] UK</td>
<td>50 deceased patients registered with one GP practice</td>
<td>To describe the prescribing and usage of anticipatory medications in the community &lt;br&gt; Methods: Retrospective notes review. Descriptive statistics</td>
<td>• 44% of deceased patients prescribed anticipatory medication &lt;br&gt; • Medication issued by diagnosis: cancer 10/16 (62%), frailty/dementia 11/22 (50%), sudden death 1/5 (20%) &lt;br&gt; • Median number of days AM issued and started [X] before death: cancer 14[4], frailty/dementia 6[4], sudden death 11[6]</td>
<td>M M M – M</td>
</tr>
<tr>
<td>Hedges et al. (2021) [15] UK</td>
<td>8 bereaved family caregivers receiving care from one specialist palliative care team</td>
<td>To explore bereaved family caregivers’ experiences, feelings and perspectives relating to when a family member was prescribed anticipatory medications at home &lt;br&gt; Methods: Qualitative interviews. Qualitative analysis</td>
<td>• Anticipatory medications were accepted in the home, despite inadequate explanation, because symptoms or suffering were expected &lt;br&gt; • Medications did not have the presumed effect: there was a perception of lack of benefit and harm</td>
<td>M H L – M</td>
</tr>
</tbody>
</table>
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Hughes et al. (2021) [16] UK | 38 bereaved family caregivers who received care from one specialist palliative care organisation (hospice or community) | To explore family caregivers' experiences of anticipatory medication and explore ways to improve practice  
 Methods: Survey 3-9 months after death. Descriptive statistics and qualitative analysis | • 87% of respondents said there were benefits of having anticipatory medications available and were reassured by their presence  
 • Some people found medicines distressing as they highlighted that death was imminent  
 • ‘Just over half’ of the respondents reported that the medication was used, usually for pain or agitation with good effect  
 • Of the patients who required medications, the problems caregivers reported were deciding when to call for help (21%); delays in clinicians attending to administer medication (29%); knowledge of the clinician attending (24%) | M M M – M |
| Katz et al. (2019) [17] Australia and New Zealand | 121 doctors: 104 consultant and 17 trainee palliative care doctors working in two countries | To explore palliative medicine doctors’ approaches to pre-emptive prescription of medications to manage catastrophic events  
 Methods: Staff Survey. Descriptive statistics | • Clinicians prescribe crisis medication to prevent poor symptom control and unrelieved distress  
 • The most commonly prescribed crisis management drugs were morphine midazolam  
 • 25% of clinicians reported being aware of adverse outcomes due to medications being prescribed for potential catastrophic events  
 • 50% were aware of adverse events related to medications not being prescribed  
 • Many clinicians reflected on a lack of evidence, a desire for further studies and standardised approaches to support practice  
 • Concerns about prescribing: discussing an unlikely event can cause disproportionate and often unnecessary anxiety; it can be challenging to know when to administer medications | M M M – M |
# Supplemental Material 3

## Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Ponnampalampillai et al. (2018) [18] UK | 132 deceased patients who accessed a county-wide community palliative care coordination centre | To evaluate anticipatory prescribing across one county Methods: Retrospective notes review. Descriptive statistics | • Recognition of the need for prescribing came from palliative care nurses (50%), GPs (32%) and community nurses (14%)  
• Median timing between anticipatory prescription and first drug administration was 9 days for patients with cancer (range 0 to 368 days), and 61 days for those with non-cancer conditions (range 3 to 298 days)  
• 37% of medications prescribed were administered | M M M – M |
| Khalil et al. (2018) [19] Australia | 29 community nurses and palliative care nurses | To identify the challenges with the administration and access to anticipatory medications in rural and remote community settings Methods: Staff Survey. Descriptive statistics | • Opioids (55%) were reported as the most commonly used anticipatory medication followed by antiemetics (45%), clonazepam (41%) and midazolam (41%)  
• Most thought it was useful to organise medications in the home  
• Barriers to prescribing: a third of all nurses indicated that doctors were not willing to prescribe drugs on some occasions due to the fear of drug misuse and/or abuse  
• Reported issues in using drugs: lack of confidence about usage and doses; pharmacy shortages; inability to access medications  
• Reported incidents included giving the wrong dose of medication and expired medications given | M M M – M |
| Rainbow (2017) [20] UK | 16 participants: 5 community palliative care nurses; 4 hospice at home nurses; 1 community nurse; 3 GPs; 1 community pharmacist; 2 relatives | To investigate experiences of prescribing, administering, dispensing and observing anticipatory medication at the end of life Methods: Qualitative interviews. Qualitative analysis | • Anticipatory prescribing and standardised systems were felt to have improved the management symptoms at the end of life | M H L – M |
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Benson et al. (2021) [21] UK | 347 deceased patients under the care of 174 hospital, 49 community and 124 hospice teams (1 patient per site) | To identify the use of syringe pumps (drivers) across a network Methods: Retrospective notes review and network discussion of results. Descriptive statistics and description | • 58% of services responding to the survey allowed anticipatory syringe pump prescribing  
• 33% of patients in the community prescribed anticipatory syringe pumps  
• Two conflicting sets of views and practices regarding anticipatory syringe pumps: some clinicians considered them vital to ensure timely symptom; others viewed it at unsafe practice, citing incidents / near-misses resulting from lack of clinical assessment of need when syringe pump started | M M L – M |
| Coyle et al. (2021) [22] UK | 223 deceased patients prescribed anticipatory syringe in part of one county during a 12-month period | Audit of anticipatory syringe driver prescription and administration practices, benchmarked against local guidance Methods: retrospective notes review. Statistical analysis and benchmarking care against local guidance | • 136/223 (61%) of anticipatory syringe pumps prescribed were used  
• None the 97/213 cases where midazolam was administered were considered unsafe  
• Only the dosages used for one of the 115 patients who received opioid administration was considered unsafe  
• Cyclizine administered to 40/158 people; antisecretories administered to 57/206 people  
• Midazolam was the only benzodiazepine given: ranges of prescription were more likely to outside of the range stated within guidance if had SPC input (p=0.04) and more likely to have it administered (p<0.0001) | M M M – M |
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Webber et al. (2019) [23] Canada</td>
<td>Population level study = 5223 patient deaths Retrospective cohort study = 4538 patient deaths</td>
<td>To evaluating the impact of a home medication kit and home-death planning tool on place of death, hospitalisations, and emergency department visits among palliative home care patients Methods: Population-level and retrospective cohort study using medical records. Statistical analysis</td>
<td>• Compared with patients who received neither intervention, patients who received the home-death planning tool or home medication kit had an increased likelihood of dying in the community, with the largest relative risk observed in patients who received both interventions • Receipt of these interventions was only associated with reductions in hospitalisation or emergency department visit rates in the six months of life</td>
</tr>
<tr>
<td>Ryan et al. (2020b) [24] UK</td>
<td>Anticipatory prescribing guidance documents from 49 areas of the UK: 5 national (representing all 4 countries) and 44 local (33 English, 11 Scottish)</td>
<td>To investigate the scope and content of UK anticipatory prescribing governance documents Methods: Qualitative and quantitative content analysis using a previously developed anticipatory prescribing process framework</td>
<td>• Anticipatory prescribing is widespread established practice in the UK, with two typologies of guidance • Type 1: AP guidance is embedded within ‘last days of life’ symptom management guidelines and is usually limited to the prescribing and administration phases • Type 2: AP guidance covers more than the ‘last days of life’ period and documents specifically address all 5 phases of the AP process</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A +B +C = D</td>
</tr>
<tr>
<td>M M L – M</td>
</tr>
<tr>
<td>M L M – L</td>
</tr>
</tbody>
</table>
## Supplemental Material 3

### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Khalil et al. (2021) [25] Australia | Stage one: 799 patient records for 25 GP practices | To map the use of end-of-life and anticipatory medications in a cohort of palliative care patients GP medical records and to discuss the results through stakeholder consultation | - 13.5% of patients with a palliative care referral flagged in their records were prescribed injectable or oral end-of-life medications  
- A referral to specialist palliative care trigger a standard request to GPs for anticipatory medications  
- Barriers to prescribing: identifying the right stage to prescribe drugs and fears of expediting death  
- Facilitators for prescribing: good working relationships between nurses and GPs; forward planning approach | L M L – L |
| Lewis et al. (2021) [26] UK | 6 family caregivers in one county | Evaluation of a scheme to train family caregivers to give anticipatory medication and the intervention's acceptability to carers | - System in place to train some family caregivers to administer medication (criteria not given)  
- Drugs started and given between 6 to 137 days before death (median: 9 days)  
- Data available for four of the six family caregivers trained: all four responded to say training was ‘acceptable’ | L M L – L |
| Ward (2020) [27] UK | 12 organisations anticipating prescribing guidance in one region (hospices, hospital and community teams) | Determining a baseline of current practice in guidance | - Guidance had a general agreement on which medications to prescribe  
- ‘Small numbers of centres’ advise on anticipatory syringe pumps | L M L – L |
### Supplemental Material 3

#### Summary of included studies

<table>
<thead>
<tr>
<th>Author and country</th>
<th>Participants</th>
<th>Study aims and methods</th>
<th>Key findings</th>
<th>Weight of evidence</th>
</tr>
</thead>
</table>
| Dredge et al. (2017) [28] Australia | 7 community palliative care nurses working for one organisation. A 'small number' of family caregivers | To measure nursing staff satisfaction with changes in anticipatory prescribing practice and early feedback on an educational programme to train family caregivers to administer injectable anticipatory medication | • Change in practice from all patients prescribed anticipatory medications to individual assessment of need by nurses based on agreed criteria (criteria not given).  
• GP prescribes medication following a request from the specialist palliative care team  
• Perceived barriers to prescribing included a lack of access to GPs  
• Medications are administered by nurses or family caregivers with suitable training  
• Relatively few caregivers both willing and able to undertake education programme  
• Reports on positive feedback from caregivers on the training to administer drugs | L L L L |

#### References


Supplemental Material 3

Summary of included studies


Supplemental Material 3

Summary of included studies


